Arterial and Venous Thromboembolism in ALK-Rearrangement-Positive Non-small Cell Lung Cancer: A Population-Based Cohort Study.

Oded IchtAvi LeaderErez BatatLilach YosefTzippy ShochatDaniel A GoldsteinElizabeth DudnikGalia SpectrePia RaananiAriel HammermanAlona Zer

Published in: The oncologist (2023)

In this study, we observed a higher VTE risk, but not ATE risk, in patients with ALK-rearranged NSCLC relative to those without ALK rearrangement. Prospective studies are warranted to evaluate thromboprophylaxis in ALK-positive NSCLC.

Keyphrases

venous thromboembolism
advanced non small cell lung cancer
epidermal growth factor receptor
small cell lung cancer
direct oral anticoagulants
tyrosine kinase
atrial fibrillation